HLTH Europe 2026: obesity drugs shift the paradigm, but systemic implementation lags
With more than one billion people globally suffering from obesity, pharmaceutical approaches to treatment, such as glucagon-like peptide 1 receptor…
16 Jun 2026
Cystic Fibrosis Foundation backs Israeli biotech with $13m to develop inhaled drug
The Cystic Fibrosis Foundation will supply up to $13m of funding to SpliSense, helping the biotech continue development of its inhaled drug candidate designed to treat the disease. SpliSense’s SPL84,…
16 Jun 2026
FDA and MHRA forge new regulatory collaboration initiative
The US Food and Drug Administration (FDA) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) will more formally collaborate to combine the agencies’ expertise, helping shape the future…
16 Jun 2026
Alkermes’ alixorexton secures FDA and EC orphan designations
Alkermes has received orphan drug designations (ODD) from both the US Food and Drug Administration (FDA) and the European Commission (EC) for alixorexton, its investigational oral orexin 2 receptor (OX2R)…
15 Jun 2026
Younger UK children to benefit from new dose of nasal spray allergy drug
Younger children in the UK will now have a needle-free option to treat serious allergic reactions after the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved a new dose…
15 Jun 2026
FDA oncology roundup: drugs, imaging agents and diagnostics gain approval
Over the last few days, the US Food and Drug Administration (FDA) has granted approval to several oncology products across both the pharmacological, imaging and companion diagnostic (CDx) realms –…
15 Jun 2026
Simcere and Stanford partner to develop IPF therapies
Simcere Pharmaceutical Group has entered a research collaboration agreement with Stanford Medicine to develop new therapies for idiopathic pulmonary fibrosis (IPF). Under the deal, Simcere will provide funding for exploratory…